Eradivir, a West Lafayette, IN-based preclinical biotech company that develops antiviral therapeutics, raised $10.25M in Series A funding.
Funding was raised with investments from Philip Low, board members and other members of the company. Additional investors were small institutions, friends and family.
The company intends to use the funds to conduct a Phase 2a challenge study of its EV25 influenza treatment.
Led by CEO Martin Low, Eradivir focuses on advancing a small-molecule, bispecific immunotherapy that tethers a patient’s immune cells specifically to a diseased cell facilitating its rapid and selective destruction. Its first drug to go into humans, EV25, is directed against influenza. EV25 was built on a platform created by Philip Low, the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in Purdue University’s College of Science.
Eradivir received $10.8M in previous funding rounds along with $1M from the National Science Foundation and the Center for Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation and Ventures.
FinSMEs
26/09/2024